VirtualPipeline OG-TW.jpg

The Epilepsy Foundation Pipeline Conference is going virtual!  

August 27-28, 2020

Registration for this event is closed

What is the Pipeline Conference?

The Pipeline Conference showcases the latest developments in the epilepsy pipeline from preclinical to right before FDA approval. This is a one-stop shop to get anyone up to speed on the landscape and latest news about epilepsy.

Registering for this event gives you:

  • Access to over 50 different presentations on products and trends in epilepsy development (See Agenda
  • Opportunity to interact with drug and device developers in the epilepsy space throughout the event
  • A week pass following the event to re-watch any of the sessions you might have missed 
  • Epilepsy Foundation Shark Tank voting to select the latest innovative idea for the Foundation to seed fund

Agenda

Times are eastern time (ET). 

Day 1 – Thursday, August 27, 2020

Welcome and Introduction – 9:00-9:10 A.M.

  • Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation  
  • Laura Thrall, President & CEO, Epilepsy Foundation

Session I: Diagnosis And Detection Devices Part I - 9:10-10:30 A.M.

  • Lectures
    • Can SUDEP be avoided with devices?– Sam Lhatoo MD, FRCP, UT Health 
    • My Seizure Gauge, Seizure Forecasting, and the Future of Therapeutics –  Dean Freestone PhD, Co-Founder, Seer Medical 
  • Diagnosis and Detection Device Pipeline Presentations 
    • SeizeIT, Byteflies & UCB – Benjamin Vandendriessche, CMO & Gergely Vertes, Seizure Freedom Mission Solution Accelerator 
    • Embrace Platform and Device, Empatica – Matteo Lai, Co-Founder & CEO
    • Epihunter Tracker, Epihunter – Dirk Loeckx PhD, Chief Scientific Officer
    • Nelli Seizure Monitoring Tool – Kaapo Annala, CEO, Neuro Event Labs
  • Q&A

Break – 10:30-10:50 A.M.

Session I: Diagnosis And Detection Devices Part II – 10:50-11:50 A.M

  • Discussion  – Unmet needs in devices for epilepsy communitymoderated by Sonya Dumanis, PhD VP of Research & Innovation, Epilepsy Foundation with key discussants Ben Brinkmann, PhD, Mayo Clinic, Sam Lhatoo MD, FRCP, UT Health ,  Mark Richardson, BMBCh, PhD, FRCP, Kings College London

  • Diagnosis and Detection Device Pipeline Presentations

    • TMS-EEG, Kings College London – Isabella Premoli MD
    • UNEEG 24/7 SubQ, UNEEG Medical – Jonas Duun-Henriksen, Head of  Epilepsy Science
    • Epi-Minder sub-scalp system, Epi-Minder – Mark Cook, Director of Neurology, Melbourne University
    • Epilog wearable device, Epitel – Mark Lehmkuhle PhD, CEO/CTO
  • Q&A

Session II/III (Parallel Tracks – 11:55 -12:30 P.M.)

Session II: Therapeutic Devices – 11:55-12:25 P.M. 

  • Therapeutic Device Pipeline Presentations
    • Cathodal Transcranial Direct Current Stimulation, tDCS, Neuroelectrics  –  Alexander Rotenberg MD 
    • DyNeuMo implantable device and platform, University of Oxford – Timothy Denison  
  • Q&A

Session III: COVID impact on recruitment to clinical trials – 11:55 -12:35 P.M. 

  • Presentation
    • Impact of COVID on Trials - Jeremy Levin, D.Phil, MB BChir, CEO Ovid Therapeutics
  • Panel moderated by Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation with Jeremy Levin, D.Phil, MB BChir, CEO Ovid Therapeutics, Board Chair of the Biotechnology Innovation Organization (BIO), Melissa Maske, person living with epilepsy, and Pavel Klein, MD, Director, Mid-Atlantic Epilepsy and Sleep Center

Break – 12:35 -1:05 P.M.

Session IV: What We Still Need In Drugs For Focal Epilepsy – 1:05-3:10 P.M.

  • Lecture
    • An Overview of the 2019 Research Roundtable for Epilepsy – Dennis Dlugos MD, Children’s Hospital of Philadelphia
  • Panel - What would make a new focal epilepsy drug successful in the marketplace.  Moderated by Daniel Friedman MD, New York University Langone Medical Center with key discussants Cynthia Harden, MD , F.A.E.S. Therapeutic Head of Epilepsy; Elinor Ben-Menachem MD, PhD, Sahlgrenska Academy; and Nathan Fountain, MD University of Virginia.
  • Drug Pipeline Presentations
    • 2-Deoxy-d-Glucose (2DG), University of Wisconsin  – Thomas Sutula MD, PhD 
    • Inhibitory interneuron cell therapy, Neurona Therapeutics – Cory Nicholas PhD, CEO & Co-Founder 
    • Revivo-5061, Revivo Therapeutics – Doug Cowart PharmD, CEO 
    • Cenobamate and Carisbamate, SK Life Sciences – William Rosenfeld MD
    • Kv7 potassium channel modulators for the treatment of epilepsy, Xenon Pharma – Ernesto Aycardi MD, Chief Medical Officer  
    • CVL-865, Cerevel Therapeutics – Rachel Gurrell 
    • mGlu2 PAM JNJ-40411813 and Levetiracetam:  A potential rational polypharmacy treatment?Janssen Research & Development, a division of Janssen Pharmaceutica N.V.  – Marc Ceusters, PhD
  • Q&A

Break – 3:10-3:40 P.M   

Update From 2019 Shark Tank Winners – 3:40-4:10 P.M.

  • Update from 2019 winner #1 – Rachel Kuperman, Eysz 
  • Update from 2019 winner #2 – Jody McNannay, Curadite

2020 Shark Tank Competition – 4:10-6:00 P.M.

  • Moderator: Sonya Dumanis, PhD, Vice President of Research and Innovation, Epilepsy Foundation

    • NAO-VNS: A disruptive implantable neurostimulator for the treatment of epilepsy – Synergia Medical 
    • Minimally invasive implantable graphene electrodes – Brain Scientific Inc.  
    • Automated privacy enhancement for seizure videos – Mocxa  
    • A night-time SUDEP prevention device – Soterya 
    • Epilepsy emergency band – Keely McCarthy, mother of a child with epilepsy   
  • Discussion, voting, and awarding  

Award to Mary Ann Brodie: Accelerator Award Virtual Reception & Presentation – 6:00 P.M. 

Day 2 – Friday, August 28, 2020 

Platform Talks - 8:05-9:05 A.M. 

  • Seer Platform, Seer Medical, Dean Freestone, PhD, Co-Founder
  • Using AI to predict AED response, UCB, Martin Armstrong, PhD, Head of Genetics 
  • Predictor of AED Response through Advanced Data analysis of EEG (PARADE), Epilog, Gregor Strobbe, PhD, Co-CEO
  • BioSerenity platform, BioSerenity, Bruce Lavin, MD, MPH, Chief Medical Officer
  • Repurposing technology to create a new normal for non-motor epilepsies, Allison Watson, Ring20 Research and Support UK CIO, Tim Buckinx, Epihunter
  • CUE Epilepsy platform based on EEG biomarkers in the MTLE mouse and GAERS model to enable drug discovery of new AEDs, Corinne Roucard, SynapCell SAS

Parallel Tracks Session V/VI: 9:05 – 10:05 A.M.

Session V: Screening – 9:05-9:50 A.M.

  • Lectures 
    • Status report on NINDS Translational Epilepsy Research – Brian Klein PhD, NINDS 
    • Screening Across the Board: Where are we and where should we be going? – Mike Rogawski MD, PhD, University California Davis 
  • Pipeline Screening Presentation
    • NeuCyte Platform, NeuCyte – Thomas Portmann PhD, Associate Director, Head of Research
  • Q&A

Session VI: Data-Driven Solutions – 9:05-9:50 A.M.

  • Lectures 
    • What can we learn from aggregated data and why should we be capturing it? – David Voccola, Prometheus Research, Co-Founder 
    • Epilepsy Digital Experience Navigator (EDEN) – Jacqueline French MD, Chief Medical Innovation Officer, Epilepsy Foundation
    • Epilepsy Learning Healthcare System – Susan Herman, MD, Barrow Neurological Institute
  • Q&A

Break – 9:50-10:05 A.M.   

Session VII: Genetics – 10:05-11:05 A.M.

  • Lecture
    • Mechanisms of intervention in single gene diseases – Ingrid Scheffer, MD, University of Melbourne
  • Gene Modifying Therapies 
    • STK-001, Stoke Therapeutics – Barry Ticho MD, PhD, Chief Medical Officer 
    • EXT101, Encoded Therapeutics – Stephanie Tagliatela, Chief Scientific Officer
  • Discussion Scaling approaches across genetic conditions
    • ​moderated by Ingrid Scheffer, MD with Barry Ticho, MD and Stephanie Tagliatela as key discussants

Session VIII: Rare And Ultra-Rare Diseases–Part I 11:05-12:20 P.M. 

  • Discussion Moving Beyond Seizures.  Moderated by Nicole Murray, Director, Epilepsy Foundation with key discussants Hillary Savoie, co-founder Cute Syndrome Foundation, Rima Nabbout MD, PhD Hôpital Necker – Enfants Malades, and Tracy Dixon-Salazar, PhD Director Research & Strategy, LGS Foundation
  • Rare and Ultra-Rare Disease Drug Therapies (Part 1) 
    • Tak-935/OV935, Takeda Pharmaceuticals – Mahnaz Asgharnejad PharmD, VP Clinical Development 
    • UX-068, Ultragenyx  – Melanie Brandabur MD, Medical Director 
    • VAL-0417 and VAL-1221, Valerion Therapeutics – Matthew Gentry PhD 
    • Epidiolex for Tuberous Sclerosis – Farhad Sahebkar MD, Senior Medical Director, Greenwich Biosciences 
  • Q&A

Lunch – 12:20-12:50 P.M.

Session VIII: Rare And Ultra-Rare Diseases–Part II 12:50-1:55 P.M. 

    • ZX008, Zogenix – Glenn Morrison PhD, VP Global Clinical Development 
    • Anavex 2-73, Anavex Life Sciences – Walter Kaufmann MD, Chief Medical Officer 
    • AE116, Aeovian Pharmaceuticals  – Stelios Tzannis PhD, President & CEO
    • PRAX-330, Praxis Precision Medicines – Kris Kahlig, PhD, Director, Biology 
    • NBI-921352, Neurocrine Biosciences – Dietrich Haubenberger MHSc, MD, Medical Director, Early Clinical Development 
  • Q&A

Session IX: Reformulated Drugs And Other Therapies – 1:55 - 3:45 P.M.

  • Discussion - How to move a repurpose drug forward.  Panel moderated by Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation with Greg Went, PhD, Former CEO of Adamas Pharmaceuticals and Mike Davis, UCB
  • Reformulated Drugs And Other Therapies Pipeline Presentation
    • Buccal diazepam, Aquestive Therapeutics – Michael Rogawski MD, PhD, Consultant 
    • Staccato alprazolam, Engage Therapeutics – Jouko Isojarvi MD, PhD, Chief Medical Officer 
    • Novel intramuscular diazepam, Xeris Pharmaceuticals – Anh Nguyen MD, Director, Strategy Operations 
    • CT-010, Cerebral Therapeutics – Dan Abrams MD, CEO 
    • The gut brain axis and epilepsy, Bloom Science – Christopher Reyes PhD, Co-Founder & CEO
    • Ganaxolone IV, Marinus Pharmaceuticals – Joe Hulihan, MD, Chief Medical Officer
    • NRL-3, Neurelis, Inc – Adrian L. Rabinowicz, MD, SVP, Clinical Development and Medical Affairs 
  • Q&A

Break - 3:45 - 4:00 P.M.

Platforms Talks 4:00 - 5:00 P.M.

  • Using Artificial Intelligence to Advance Epilepsy Treatment, Doc.AI, Sam De Brouwer, PhD, Co-Founder
  • Epistemic app, Epistemic, Paula Gomez, PhD, MBA, CEO and Co-founder
  • Reverse Engineering the Ketogenic Diet, Jim Sonner, MD, University of California, San Francisco
  • Can Machine Learning Improve Randomized Clinical Trial Analysis?, Daniel Goldenholz, MD, PhD, M HSc, Beth Isreal Deaconess Medical Center
  • Rare Epilepsy Landscape Analysis (RELA), Ilene Miller, JD

Closing Remarks – 5:00 P.M.

  • Jacqueline French MD, Chief Medical and Innovation Officer, Epilepsy Foundation 

Innovation and Action to END EPILEPSY

Are you someone impacted by epilepsy? Following the Pipeline Conference, join us for Innovation and Action to END EPILEPSY on August 29, a nationwide virtual community day organized by and for people affected by epilepsy.  

Thank You to Our Sponsors

Thank you for your support to make the 2020 Epilepsy Foundation Pipeline Conference a successful event and your commitment to the epilepsy community.

2020 Pipeline Conference Sponsors

Watch Footage from the 2018 Pipeline Conference

Authored By: 
Epilepsy Foundation Research
Authored Date: 
05/2020